Echocardiographic and electrocardiographic identification of those children with hypertrophic cardiomyopathy who should be considered at high-risk of dying suddenly

Cardiology in the Young

Volumn 15, Issue 6, 2005, Pages 632-642

  Östman Smith, Ingegerd ^a,b   Wettrell, Göran ^c   Keeton, Barry ^d   Riesenfeld, Tomas ^e   Holmgren, Daniel ^a   Ergander, Ulf ^f  

^a QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Heart failure; Propranolol; Risk factors; Sudden death; Verapamil

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; METOPROLOL; PROPRANOLOL; VERAPAMIL;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD; CLINICAL ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG MEGADOSE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE WALL; HEART VENTRICLE SEPTUM; HIGH RISK PATIENT; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MORTALITY; NOONAN SYNDROME; OUTCOMES RESEARCH; PREDICTION; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SUDDEN DEATH;

ADOLESCENT; CARDIOMYOPATHY, HYPERTROPHIC; CHILD; CHILD, PRESCHOOL; DEATH, SUDDEN, CARDIAC; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 28644434529     PISSN: 10479511     EISSN: 14671107     Source Type: Journal    
DOI: 10.1017/S1047951105001824     Document Type: Article

References (30)

1. Sugishita Y, Matsuda M, Iida K, Koshinaga J, Ueno M. Sudden cardiac death at exertion. Jpn Circ J 1983; 47: 562-572.
2. Maron B, Roberts W, McAllister H, Rosing DR, Epstein SE. Sudden death in young athletes. Circulation 1980; 62: 218-229.
3. Fananapazir L, Epstein ND. Prevalence of hypertrophic cardiomyopathy and limitations of screening methods. Circulation 1995; 92: 700-704.
4. Arola A, Jokinen E, Ruuskanen O, et al. Epidemiology of idiopathic cardiomyopathies in children and adolescents: A nationwide study in Finland. Am J Epidemiol 1997; 146: 385-393.
5. Lipshultz SE, Sleeper LA, Towbin JA, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 2003; 348: 1647-1655.
6. McKenna W, Deanfield J, Faruqui A, England D, Oakley C, Goodwin J. Prognosis in hypertrophic cardiomyopathy: Role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 1981; 47: 532-538.
7. Maron BJ, Mathenge R, Casey SA, Poliac LC, Longe TF. Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities. J Am Coll Cardiol 1999; 33: 1590-1595.
8. Östman-Smith I, Wettrell G, Riesenfeld T. A cohort study of childhood hypertrophic cardiomyopathy: Improved survival following high-dose beta-adrenoceptor antagonist treatment. J Am Coll Cardiol 1999; 34: 1813-1822.
9. McKenna WJ, England D, Doi YL, Deanfield JE, Oakley C, Goodwin JF. Arrhythmia in hypertrophic cardiomyopathy. I: Influence on prognosis. Br Heart J 1981; 46: 168-172.
10. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy. an independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003; 42: 873-879.
11. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 1778-1785.
12. Maron B, Lipson L, Roberts W, Savage DD, Epstein SE. "Malignant" hypertrophic cardiomyopathy: Identification of a subgroup of families with unusually frequent premature death. Am J Cardiol 1978; 41: 1133-1140.
13. Sadoul N, Prasad K, Elliott PM, Bannerjee S, Frenneaux MP, McKenna WJ. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 1997; 96: 2987-2991.
14. Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003; 348: 295-303.
15. Cecchi F, Olivotto I, Montereggi A, Squillatini G, Dolara A, Maron BJ. Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population. Heart 1998; 79: 331-336.
16. Olivotto I, Maron BJ, Montereggi A, Mazzuoli F, Dolara A, Cecchi F. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999; 33: 2044-2051.
17. Elliott PM, Gimeno Blanes JR, Mahon NG, Poloniecki JD, McKenna WJ. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001; 357: 420-424.
18. Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J 1949; 37: 161-186.
19. Sahn D, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitaion in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083.
20. Östman-Smith I, Devlin AM. A simple method for assessing the regression or progression of ventricular hypertrophy in the growing child and adult: The value of left ventricular wall-to-cavity ratios. Eur J Echocardiogr 2001; 2: 22-30.
21. Maron BJ, Henry NL, Clark CE, Redwood DR, Roberts WC, Epstein SE. Asymmetric septal hypertrophy in childhood. Circulation 1976; 53: 9-19.
22. McKenna WJ, Deanfield JE. Hypertrophic cardiomyopathy: An important cause of sudden death. Arch Dis Child 1984; 59: 971-975.
23. Yetman AT, Hamilton RM, Benson LN, McCrindle BW. Long-term outcome and prognostic determinants in children with hypertrophic cardiomyopathy. J Am Coll Cardiol 1998; 32: 1943-1950.
24. Ackerman M, VanDriest S, Ommen S, et al. Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and Troponin T genes in hypertrophic cardiomyopathy: A comprehensive outpatient perspective. J Am Coll Cardiol 2002; 39: 2042-2048.
25. Mayosi BM, Keavney B, Kardos A, et al. Electrocardiographic measures of left ventricular hypertrophy show greater heritability than echocardiographic left ventricular mass. Eur Heart J 2002; 23: 1963-1971.
26. Havndrup O, Bundgaard H, Andersen PS, et al. Outcome of clinical versus genetic family screening in hypertrophic cardiomyopathy with focus on cardiac beta-myosin gene mutations. Cardiovasc Res 2002; 57: 347-357.
27. Blair E, Redwood C, Ashrafian H, et al. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: Evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet 2001; 10: 1215-1220.
28. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: Identification of high risk patients. J Am Coll Cardiol 2000; 36: 2212-2218.
29. Devlin AM, Ostman-Smith I. Diagnosis of hypertrophic cardiomyopathy and screening for the phenotype suggestive of gene carriage in familial disease: A simple echocardiographic procedure. J Med Screen 2000; 7: 82-90.
30. Hjalmarson A. Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter? Basic Res Cardiol 2000; 95 (Suppl 1): I141-I145.